Foundation Announces New Board Members and New Advisory Board Members
ATLANTA, November 15, 2013 – The Foundation for Mitochondrial Medicine, a 501(C)3 that funds the development of the most promising research and treatments of the many forms of mitochondrial disease, announces three new members to its board of directors and six new advisory committee members. The new members to the board of directors include:
Fred Blankenship, morning and noon news anchor for WSB-TV. Blankenship joined the WSB-TV family in 2007. Before coming to Atlanta he worked six years at San Diego’s KGTV as a reporter and weekend anchor. In San Diego, he won awards for stories on drug prevention and community outreach, and many of the stories Blankenship covered focused on the growing problem of gangs. Prior to KGTV, Fred worked at both KAKE TV in Wichita, Kansas and KRON in San Francisco. He is a member of the National Association of Black Journalists and also a member of the National Press Photographers Association. He is a native of Los Angeles, and he received his undergraduate degree from the University of San Francisco.
Dick Boger is semi-retired and president and chief executive officer of Lex-Tek International Inc., a financial services consulting company. Boger joined Lex-Tek in 2002 and was previously president and chief executive officer of Export Insurance Services Inc. He has also served as trustee in Owen Holdings, LLLP, and as a general partner/trustee of Shawnee Meadow Holdings, LLLP and Heathland Holdings, LLLP, all family investment partnerships, and Boger-Owen Foundation, a 501 ( c ) 3 nonprofit. Boger was co-founder and a chairman of Boger, Reid & Flournoy, a commercial insurance brokerage, now a part of Brown & Brown (NASDAQ). He serves on the board of directors for Gray Television Inc. (NYSE) and CornerCap Mutual Funds, a Series Mutual Fund. He also serves on various nonprofit boards, including The Bascom, a visual arts center in Highlands, N.C. Boger earned his bachelor’s degree in economics from the University of Michigan and lives in Highlands and Atlanta.
Anthony Soscia, founder and President of Atlantic Pharmaceuticals since 2004. Atlantic Pharmaceuticals is a specialty pharmaceutical company using its patented technology to produce novel therapeutics that resist attempts at tampering and may be useful to reduce abuse of certain prescription drugs. Based on the Company’s proprietary technology, SMART/Script™, Atlantic is developing a pipeline of abuse-deterrent products that are nearing pivotal testing. SMART/Script™ (SMART, Simple, controllable, resistant, insoluble, physical trap) a novel, patented drug delivery technology, was designed to prevent easy drug extraction and to deter the abuse of medications via known routes of abuse or misuse, including chewing, snorting, and injecting. Soscia was selected as a finalist for Atlanta’s Health Care Heroes in 2013. Prior to joining Atlantic Pharmaceuticals, he was in business development roles with UK based Bioprogress and Roussel Aventis. Soscia received his bachelor’s degree in biology from Northwestern University and his master’s degree in nutrition and food science from the University of Arizona.
The Foundation’s newest advisory committee members include:
Bob Baxter, Senior Client Partner/Managing Director Atlanta, Korn/Ferry International; Nate Bennett, Professor, Robinson College of Business at Georgia State University; Paula Bevington, Principal of Bevington Advisors; Brian Dorrien, Direct of Client Services at Venadar; Rich Fabritius, Managing Director, Brunner Advertising; and Russ Lipari, President of Validus Group & Chairman Health Leadership Council, United Way Atlanta.
About the Foundation for Mitochondrial Medicine (FMM)
The Foundation for Mitochondrial Medicine’s mission is to support the development of the most promising research and treatments for the many forms of mitochondrial disease. Cures for mitochondrial diseases could impact cures for Autism, Alzheimer’s, Parkinson’s, and Lou Gehrig’s disease among others. For more information on FMM funded research such as functional MRI studies on cognitive fatigue and testing of new drug compounds, visit www.mitochondrialdiseases.org
# # #
Media contact: Jennifer Grizzle, 404.291.1310 or firstname.lastname@example.org